-$0.24 EPS Expected for Pear Therapeutics, Inc. (NASDAQ:PEAR) This Quarter

Equities analysts expect Pear Therapeutics, Inc. (NASDAQ:PEARGet Rating) to report earnings of ($0.24) per share for the current quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Pear Therapeutics’ earnings, with estimates ranging from ($0.24) to ($0.23). The business is scheduled to report its next earnings report on Monday, January 1st.

According to Zacks, analysts expect that Pear Therapeutics will report full year earnings of ($0.88) per share for the current year, with EPS estimates ranging from ($0.95) to ($0.83). For the next year, analysts anticipate that the firm will post earnings of ($0.74) per share, with EPS estimates ranging from ($0.95) to ($0.52). Zacks’ EPS averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Pear Therapeutics.

Several brokerages have commented on PEAR. Zacks Investment Research raised Pear Therapeutics from a “hold” rating to a “buy” rating and set a $5.75 target price on the stock in a report on Friday, April 1st. Citigroup decreased their target price on Pear Therapeutics from $13.00 to $12.00 and set a “buy” rating for the company in a research report on Tuesday, March 29th. Bank of America initiated coverage on Pear Therapeutics in a report on Wednesday, January 26th. They set a “neutral” rating for the company. BTIG Research began coverage on Pear Therapeutics in a report on Monday, January 3rd. They set a “buy” rating and a $12.00 price objective for the company. Finally, Credit Suisse Group assumed coverage on Pear Therapeutics in a report on Thursday, January 20th. They issued an “outperform” rating and a $11.00 target price for the company. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $10.19.

Large investors have recently made changes to their positions in the company. Sciencast Management LP purchased a new stake in shares of Pear Therapeutics during the first quarter worth about $190,000. EDBI Pte Ltd bought a new stake in shares of Pear Therapeutics during the fourth quarter valued at approximately $2,644,000. Penserra Capital Management LLC bought a new stake in shares of Pear Therapeutics during the fourth quarter valued at approximately $37,000. Sarissa Capital Management LP bought a new stake in Pear Therapeutics in the 4th quarter worth approximately $3,102,000. Finally, SB Global Advisers Ltd bought a new stake in Pear Therapeutics in the 4th quarter worth approximately $75,020,000.

NASDAQ PEAR opened at $5.16 on Friday. Pear Therapeutics has a twelve month low of $3.46 and a twelve month high of $14.60. The firm’s fifty day moving average price is $4.61.

Pear Therapeutics Company Profile (Get Rating)

Pear Therapeutics, Inc, a commercial-stage healthcare company, develops and sells software-based medicines. Its commercial products are reSET for the treatment of substance use disorder related to alcohol, cannabis, cocaine, and stimulants; reSET-O for the treatment of opioid use disorder in combination with buprenorphine; and Somryst, a software-based treatment for chronic insomnia.

Further Reading

Get a free copy of the Zacks research report on Pear Therapeutics (PEAR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Pear Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pear Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.